Neuroinflammation, microglia and implications for anti-inflammatory treatment in Alzheimer's disease

International Journal of Alzheimer's Disease

Volumn , Issue , 2010, Pages

  Krause, Daniela L ^a   Müller, Norbert ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYANTHRANILIC ACID; AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; ARACHIDONIC ACID; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; GLUTAMIC ACID; IBUPROFEN; INDOMETACIN; LIPOPOLYSACCHARIDE; MEMANTINE; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLACEBO; PROSTAGLANDIN SYNTHASE INHIBITOR; QUINOLINIC ACID; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 6; ROFECOXIB; STEROID; SULINDAC SULFIDE; TUMOR NECROSIS FACTOR ALPHA;

ALLOSTERISM; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; BRAIN; BRAIN CORTEX; BRAIN DAMAGE; BRAIN TISSUE; CELL ACTIVATION; CLINICAL TRIAL; COHORT ANALYSIS; DEMENTIA; DISEASE COURSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; EXCITOTOXICITY; FUNCTIONAL DISEASE; HISTOPATHOLOGY; HUMAN; INFLAMMATION; MICROGLIA; NERVE CELL DEGENERATION; NEUROINFLAMMATION; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SYMPTOM; TREATMENT INDICATION;

EID: 77955973836     PISSN: None     EISSN: 20900252     Source Type: Journal    
DOI: 10.4061/2010/732806     Document Type: Review

References (89)

1. Gtz J., Gtz N. N., Animal models for Alzheimer's disease and frontotemporal dementia: a perspective ASN Neuro 2009 1 4, article e00019
2. Teunissen C. E., van Boxtel M. P. J., Bosma H., Jolles J., Ltjohann D., Von Bergmann K., Wauters A., Bosmans E., Maes M., Delanghe J., De Bruijn C., Steinbusch H. W. M., Blom H. J., De Vente J., Serum markers in relation to cognitive functioning in an aging population: results of the Maastricht Aging Study (MAAS) Tijdschrift voor Gerontologie en Geriatrie 2003 34 1 6 12
3. McGeer E. G., McGeer P. L., Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy Journal of Alzheimer's Disease 2010 19 1 355 361
4. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G. M., Cooper N. R., Eikelenboom P., Emmerling M., Fiebich B. L., Finch C. E., Frautschy S., Griffin W. S. T., Hampel H., Hull M., Landreth G., Lue L.-F., Mrak R., MacKenzie I. R., McGeer P. L., O'Banion M. K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F. L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., Wyss-Coray T., Inflammation and Alzheimer's disease Neurobiology of Aging 2000 21 3 383 421
5. in 't Veld B. A., Ruitenberg A., Hofman A., Launer L. J., Van Duijn C. M., Stijnen T., Breteler M. M. B., Stricker B. H. C., Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease The New England Journal of Medicine 2001 345 21 1515 1521
6. Szekely C. A., Breitner J. C. S., Fitzpatrick A. L., Rea T. D., Psaty B. M., Kuller L. H., Zandi P. P., NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type Neurology 2008 70 1 17 24
7. Anthony J. C., Breitner J. C. S., Zandi P. P., Meyer M. R., Jurasova I., Norton M. C., Stone S. V., Reduced prevalence of AD in users of NSAIDS and H2 receptor antagonists: the Cache County study Neurology 2000 54 11 2066 2071
8. Reines S. A., Block G. A., Morris J. C., Liu G., Nessly M. L., Lines C. R., Norman B. A., Baranak C. C., No effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study Neurology 2004 62 1 66 71
9. Kipnis J., Cohen H., Cardon M., Z Y. IV, Schwartz M., T cell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions Proceedings of the National Academy of Sciences of the United States of America 2004 101 21 8180 8185
10. Ziv Y., Ron N., Butovsky O., Landa G., Sudai E., Greenberg N., Cohen H., Kipnis J., Schwartz M., Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood Nature Neuroscience 2006 9 2 268 275
11. Wyss-Coray T., Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nature Medicine 2006 12 9 1005 1015
12. Edison P., Archer H. A., Gerhard A., Hinz R., Pavese N., Turkheimer F. E., Hammers A., Tai Y. F., Fox N., Kennedy A., Rossor M., Brooks D. J., Microglia, amyloid, and cognition in Alzheimer's disease: an [11C](R)PK11195-PET and [11C]PIB-PET study Neurobiology of Disease 2008 32 3 412 419
13. Rogers J., Shen Y., A perspective on inflammation in Alzheimer's disease Annals of the New York Academy of Sciences 2000 924 132 135
14. Perry V. H., Newman T. A., Cunningham C., The impact of systemic infection on the progression of neurodegenerative disease Nature Reviews Neuroscience 2003 4 2 103 112
15. Mulugeta E., Molina-Holgado F., Elliott M. S., Hortobagyi T., Perry R., Kalaria R. N., Ballard C. G., Francis P. T., Inflammatory mediators in the frontal lobe of patients with mixed and vascular dementia Dementia and Geriatric Cognitive Disorders 2008 25 3 278 286
16. Stbner S., Schn T., Padberg F., Teipel S. J., Schwarz M. J., Haslinger A., Buch K., Dukoff R., Lasser R., Mller N., Sunderland T., Rapoport S. I., Mller H.-J., Hampel H., Interleukin-6 and the soluble IL-6 receptor are decreased in cerebrospinal fluid of geriatric patients with major depression: no alteration of soluble gp130 Neuroscience Letters 1999 259 3 145 148
17. Wang X.-Q., Peng Y.-P., Lu J.-H., Cao B.-B., Qiu Y.-H., Neuroprotection of interleukin-6 against NMDA attack and its signal transduction by JAK and MAPK Neuroscience Letters 2009 450 2 122 126
18. Lue L.-F., Brachova L., Civin W. H., Rogers J., Inflammation, A deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration Journal of Neuropathology and Experimental Neurology 1996 55 10 1083 1088
19. Webster S., Lue L.-F., Brachova L., Tenner A. J., McGeer P. L., Terai K., Walker D. G., Bradt B., Cooper N. R., Rogers J., Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease Neurobiology of Aging 1997 18 4 415 421
20. del Rio-Hortega P., Art and artifice in the science of histology Histopathology 1993 22 6 515 525
21. Block M. L., Zecca L., Hong J.-S., Microglia-mediated neurotoxicity: uncovering the molecular mechanisms Nature Reviews Neuroscience 2007 8 1 57 69
22. Cras P., Kawai M., Siedlak S., Mulvihill P., Gambetti P., Lowery D., Gonzalez-DeWhitt P., Greenberg B., Perry G., Neuronal and microglial involvement in -amyloid protein deposition in Alzheimer's disease American Journal of Pathology 1990 137 2 241 246
23. Styren S. D., Civin W. H., Rogers J., Molecular, cellular, and pathologic characterization of HLA-DR immunoreactivity in normal elderly and Alzheimer's disease brain Experimental Neurology 1990 110 1 93 104
24. Perlmutter L. S., Barron E., Chui H. C., Morphologic association between microglia and senile plaque amyloid in Alzheimer's disease Neuroscience Letters 1990 119 1 32 36
25. Lue L.-F., Rydel R., Brigham E. F., Yang L.-B., Hampel H., Murphy G. M. Jr., Brachova L., Yan S.-D., Walker D. G., Shen Y., Rogers J., Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro GLIA 2001 35 1 72 79
26. Simard A. R., Rivest S., Bone marrow stem cells have the ability to populate the entire central nervous system into fully differentiated parenchymal microglia FASEB Journal 2004 18 9 998 1000
27. Majumdar A., Cruz D., Asamoah N., Buxbaum A., Sohar I., Lobel P., Maxfield F. R., Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils Molecular Biology of the Cell 2007 18 4 1490 1496
28. Koenigsknecht-Talboo J., Landreth G. E., Microglial phagocytosis induced by fibrillar -amyloid and IgGs are differentially regulated by proinflammatory cytokines Journal of Neuroscience 2005 25 36 8240 8249
29. Fan R., Xu F., Previti M. L., Davis J., Grande A. M., Robinson J. K., Van Nostrand W. E., Minocycline reduces microglial activation and improves behavioral deficits in a transgenic model of cerebral microvascular amyloid Journal of Neuroscience 2007 27 12 3057 3063
30. Seabrook T. J., Jiang L., Maier M., Lemere C. A., Minocycline affects microglia activation, A deposition, and behavior in APP-tg mice GLIA 2006 53 7 776 782
31. Chaves C., Marque C. R., Trzesniak C., Machado De Sousa J. P., Zuardi A. W., Crippa J. A. S., Dursun S. M., Hallak J. E., Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update Brazilian Journal of Medical and Biological Research 2009 42 11 1002 1014
32. Wyss-Coray T., Lin C., Yan F., Yu G.-Q., Rohde M., Mcconlogue L., Masliah E., Mucke L., TGF- 1 promotes microglial amyloid- clearance and reduces plaque burden in transgenic mice Nature Medicine 2001 7 5 612 618
33. Persson M., Brantefjord M., Hansson E., Rnnbck L., Lipopolysaccharide increases microglial GLT-1 expression and glutamate uptake capacity in vitro by a mechanism dependent on TNF- GLIA 2005 51 2 111 120
34. Francis P. T., Altered glutamate neurotransmission and behaviour in dementia: evidence from studies of memantine Current Molecular Pharmacology 2009 2 1 77 82
35. Kim S. U., de Vellis J., Microglia in health and disease Journal of Neuroscience Research 2005 81 3 302 313
36. Hanisch U.-K., Kettenmann H., Microglia: active sensor and versatile effector cells in the normal and pathologic brain Nature Neuroscience 2007 10 11 1387 1394
37. Vehmas A. K., Kawas C. H., Stewart W. F., Troncoso J. C., Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease Neurobiology of Aging 2003 24 2 321 331
38. Remarque E. J., Bollen E. L. E. M., Weverling-Rijnsburger A. W. E., Laterveer J. C., Blauw G. J., Westendorp R. G. J., Patients with Alzheimer's disease display a pro-inflammatory phenotype Experimental Gerontology 2001 36 1 171 176
39. Innamorato N. G., Lastres-Becker I., Cuadrado A., Role of microglial redox balance in modulation of neuroinflammation Current Opinion in Neurology 2009 22 3 308 314
40. Espey M. G., Chernyshev O. N., Reinhard J. F. Jr., Namboodiri M. A. A., Colton C. A., Activated human microglia produce the excitotoxin quinolinic acid NeuroReport 1997 8 2 431 434
41. Giulian D., Senile plaques stimulate microglia to release a neurotoxin found in Alzheimer brain Neurochemistry International 1995 27 1 119 137
42. Leipnitz G., Schumacher C., Dalcin K. B., Scussiato K., Solano A., Funchal C., Dutra-Filho C. S., Wyse A. T. S., Wannmacher C. M. D., Latini A., Wajner M., In vitro evidence for an antioxidant role of 3-hydroxykynurenine and 3-hydroxyanthranilic acid in the brain Neurochemistry International 2007 50 1 83 94
43. Thomas S. R., Witting P. K., Stocker R., 3-hydroxyanthranilic acid is an efficient, cell-derived co-antioxidant for -tocopherol, inhibiting human low density lipoprotein and plasma lipid peroxidation Journal of Biological Chemistry 1996 271 51 32714 32721
44. Smith W. L., Michael Garavito R., DeWitt D. L., Prostaglandin endoperoxide H syntheses (cyclooxygenases)-1 and -2 Journal of Biological Chemistry 1996 271 52 33157 33160
45. Aisen P. S., Davis K. L., The search for disease-modifying treatment for Alzheimer's disease Neurology 1997 48 5 S35 S41
46. Hirst W. D., Young K. A., Newton R., Allport V. C., Marriott D. R., Wilkin G. P., Expression of COX-2 by normal and reactive astrocytes in the adult rat central nervous system Molecular and Cellular Neurosciences 1999 13 1 57 68
47. Hauss-Wegrzyniak B., Vraniak P., Wenk G. L., The effects of a novel NSAID on chronic neuroinflammation are age dependent Neurobiology of Aging 1999 20 3 305 313
48. Planas A. M., Soriano M. A., Rodrquez-Farr E., Ferrer I., Induction of cyclooxygenase-2 mRNA and protein following transient focal ischemia in the rat brain Neuroscience Letters 1995 200 3 187 190
49. Tocco G., Freire-Moar J., Schreiber S. S., Sakhi S. H., Aisen P. S., Pasinetti G. M., Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer's disease Experimental Neurology 1997 144 2 339 349
50. Pasinetti G. M., Aisen P. S., Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain Neuroscience 1998 87 2 319 324
51. Matsuoka Y., Picciano M., Maleste B., LaFrancois J., Zehr C., Daeschner J. M., Olschowka J. A., Fonseca M. I., O'Banion M. K., Tenner A. J., Lemere C. A., Duff K., Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease American Journal of Pathology 2001 158 4 1345 1354
52. Hewett S. J., Uliasz T. F., Vidwans A. S., Hewett J. A., Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture Journal of Pharmacology and Experimental Therapeutics 2000 293 2 417 425
53. Willard L. B., Hauss-Wegrzyniak B., Danysz W., Wenk G. L., The cytotoxicity of chronic neuroinflammation upon basal forebrain cholinergic neurons of rats can be attenuated by glutamatergic antagonism or cyclooxygenase-2 inhibition Experimental Brain Research 2000 134 1 58 65
54. Kunz T., Oliw E. H., The selective cyclooxygenase-2 inhibitor rofecoxib reduces kainate-induced cell death in the rat hippocampus European Journal of Neuroscience 2001 13 3 569 575
55. Araki E., Forster C., Dubinsky J. M., Ross M. E., Iadecola C., Cyclooxygenase-2 inhibitor NS-398 protects neuronal cultures from lipopolysaccharide-induced neurotoxicity Stroke 2001 32 10 2370 2375
56. Yasojima K., Schwab C., McGeer E. G., McGeer P. L., Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs Brain Research 1999 830 2 226 236
57. Ho L., Purohit D., Haroutunian V., Luterman J. D., Willis F., Naslund J., Buxbaum J. D., Mohs R. C., Aisen P. S., Pasinetti G. M., Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease Archives of Neurology 2001 58 3 487 492
58. Lukiw W. J., Bazan N. G., Cyclooxygenase 2 RNA message abundance, stability, and hypervariability in sporadic Alzheimer neocortex Journal of Neuroscience Research 1997 50 6 937 945
59. Chang J. W., Coleman P. D., O'Banion M. K., Prostaglandin G/H synthase-2 (cyclooxygenase-2) mRNA expression is decreased in Alzheimer's disease Neurobiology of Aging 1996 17 5 801 808
60. Montine T. J., Sidell K. R., Crews B. C., Markesbery W. R., Marnett L. J., Roberts L. J. II, Morrow J. D., Elevated CSF prostaglandin E2 levels in patients with probable AD Neurology 1999 53 7 1495 1498
61. Lee R. K. K., Knapp S., Wurtman R. J., Prostaglandin E2 stimulates amyloid precursor protein gene expression: inhibition by immunosuppressants Journal of Neuroscience 1999 19 3 940 947
62. Blom M. A. A., Van Twillert M. G. H., de Vries S. C., Engels F., Finch C. E., Veerhuis R., Eikelenboom P., NSAIDS inhibit the IL-1 -induced IL-6 release from human post-mortem astrocytes: the involvement of prostaglandin E2 Brain Research 1997 777 1-2 210 218
63. Fiebich B. L., Hll M., Lieb K., Gyufko K., Berger M., Bauer J., Prostaglandin E2 induces interleukin-6 synthesis in human astrocytoma cells Journal of Neurochemistry 1997 68 2 704 709
64. Kelley K. A., Ho L., Winger D., Freire-Moar J., Borelli C. B., Aisen P. S., Pasinetti G. M., Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2 American Journal of Pathology 1999 155 3 995 1004
65. Pasinetti G. M., Cyclooxygenase and inflammation in Alzheimer's disease: experimental approaches and clinical interventions Journal of Neuroscience Research 1998 54 1 1 6
66. Jiang C., Ting A. T., Seed B., PPAR- agonists inhibit production of monocyte inflammatory cytokines Nature 1998 391 6662 82 86
67. Lehmann J. M., Lenhard J. M., Oliver B. B., Ringold G. M., Kliewer S. A., Peroxisome proliferator-activated receptors and are activated by indomethacin and other non-steroidal anti-inflammatory drugs Journal of Biological Chemistry 1997 272 6 3406 3410
68. Ricote M., Li A. C., Willson T. M., Kelly C. J., Glass C. K., The peroxisome proliferator-activated receptor- is a negative regulator of macrophage activation Nature 1998 391 6662 79 82
69. Combs C. K., Johnson D. E., Cannady S. B., Lehman T. M., Landreth G. E., Identification of microglial signal transduction pathways mediating a neurotoxic response to amyloidogenic fragments of -amyloid and prion proteins Journal of Neuroscience 1999 19 3 928 939
70. Combs C. K., Johnson D. E., Karlo J. C., Cannady S. B., Landreth G. E., Inflammatory mechanisms in Alzheimer's disease: inhibition of -amyloid-stimulated proinflammatory responses and neurotoxicity by PPAR agonists Journal of Neuroscience 2000 20 2 558 567
71. Ansari M. A., Scheff S. W., Oxidative stress in the progression of alzheimer disease in the frontal cortex Journal of Neuropathology and Experimental Neurology 2010 69 2 155 167
72. Smith M. A., Zhu X., Tabaton M., Liu G., McKeel Jr. D. W., Cohen M. L., Wang X., Siedlak S. L., Dwyer B. E., Hayashi T., Nakamura M., Nunomura A., Perry G., Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment Journal of Alzheimer's Disease 2010 19 1 353 372
73. Schipper H. M., Song W., Zukor H., Hascalovici J. R., Zeligman D., Heme oxygenase-1 and neurodegeneration: expanding frontiers of engagement Journal of Neurochemistry 2009 110 2 469 485
74. Alcaraz M. J., Fernandez P., Guilln M. I., Anti-inflammatory actions of the heme oxygenase-1 pathway Current Pharmaceutical Design 2003 9 30 2541 2551
75. Cuadrado A., Rojo A. I., Heme oxygenase-1 as a therapeutic target in neurodegenerative diseases and brain infections Current Pharmaceutical Design 2008 14 5 429 442
76. Kimura K., Mechanisms of active oxygen species reduction by non-steroidal anti-inflammatory drugs International Journal of Biochemistry and Cell Biology 1997 29 3 437 446
77. Nivsarkar M., Banerjee A., Padh H., Cyclooxygenase inhibitors: a novel direction for Alzheimer's management Pharmacological Reports 2008 60 5 692 698
78. Guardia-Laguarta C., Pera M., Lle A, -secretase as a therapeutic target in Alzheimer's disease Current Drug Targets 2010 11 4 506 517
79. Weggen S., Eriksen J. L., Das P., Sagi S. A., Wang R., Pietrzik C. U., Findlay K. A., Smith T. E., Murphy M. P., Bulter T., Kang D. E., Marquez-Sterling N., Golde T. E., Koo E. H., A subset of NSAIDs lower amyloidogenic A 42 independently of cyclooxygenase activity Nature 2001 414 6860 212 216
80. Kukar T., Murphy M. P., Eriksen J. L., Sagi S. A., Weggen S., Smith T. E., Ladd T., Khan M. A., Kache R., Beard J., Dodson M., Merit S., Ozols V. V., Anastasiadis P. Z., Das P., Fauq A., Koo E. H., Golde T. E., Diverse compounds mimic Alzheimer disease-causing mutations by augmenting A 42 production Nature Medicine 2005 11 5 545 550
81. Lle A., Berezovska O., Herl L., Raju S., Deng A., Bacskai B. J., Frosch M. P., Irizarry M., Hyman B. T., Nonsteroidal anti-inflammatory drugs lower A 42 and change presenilin 1 conformation Nature Medicine 2004 10 10 1065 1066
82. McGeer P. L., Schulzer M., McGeer E. G., Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies Neurology 1996 47 2 425 432
83. Vlad S. C., Miller D. R., Kowall N. W., Felson D. T., Protective effects of NSAIDs on the development of Alzheimer disease Neurology 2008 70 19 1672 1677
84. Martin B. K., Szekely C., Brandt J., Piantadosi S., Breitner J. C. S., Craft S., Evans D., Green R., Mullan M., Cognitive function over time in the Alzheimer's disease anti-inflammatory prevention trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib Archives of Neurology 2008 65 7 896 905
85. Wolfson C., Perrault A., Moride Y., Esdaile J. M., Abenhaim L., Momoli F., A case-control analysis of nonsteroidal anti-inflammatory drugs and Alzheimer's disease: are they protective? Neuroepidemiology 2002 21 2 81 86
86. Craft J. M., Watterson D. M., Van Eldik L. J., Human amyloid -induced neuroinflammation is an early event in neurodegeneration GLIA 2006 53 5 484 490
87. Yermakova A. V., Kerry O'Banion M., Downregulation of neuronal cyclooxygenase-2 expression in end stage Alzheimer's disease Neurobiology of Aging 2001 22 6 823 836
88. Combrinck M., Williams J., De Berardinis M. A., Warden D., Puopolo M., Smith A. D., Minghetti L., Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer's disease Journal of Neurology, Neurosurgery and Psychiatry 2006 77 1 85 88
89. Aisen P. S., The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease Lancet Neurology 2002 1 5 279 284